ImmTOR-IL

ImmTOR-IL is an investigational **combination immunology therapy** from Selecta Biosciences built from the company\u2019s ImmTOR platform. It combines **biodegradable rapamycin-loaded nanoparticles** with an **engineered Treg-selective interleukin-2 mutein** to promote the induction, expansion, and durability of **antigen-specific regulatory T cells** when administered with a relevant target antigen. The program was positioned for **T-cell mediated autoimmune diseases**, with particular emphasis on **autoimmune liver diseases** such as primary biliary cholangitis, and has also been described in preclinical work for type 1 diabetes. Based on the provided information, the program remained **preclinical/in development** and was later **paused due to financial constraints while Selecta sought partnership opportunities**.

Other names

ImmTOR-ILImmTOR + IL-2 mutein